Exo’s cardiac and lung AI applications are now available on Exo Iris, its handheld ultrasound device.
The company released Exo Iris last year. The point-of-care-ultrasound (POCUS) device now features pulsed-wave Doppler capabilities to offer physicians more opportunities to assess blood velocity and thus support diagnosis and deeper findings in cardiac, abdominal, and vascular applications, according to the firm.
Exo has U.S. Food and Drug Administration (FDA) 510k clearances for cardiac, lung, bladder, hip, and thyroid applications, and plans to double the number of clearances by 2025, it said.
